TY  - CHAP
M1  - Book, Section
TI  - Cardiometabolic Disease: Insulin Resistance, Obesity, and the Metabolic Syndrome
A1  - Garvey, W. Timothy
A1  - Mechanick, Jeffrey I.
A2  - Fuster, Valentin
A2  - Narula, Jagat
A2  - Vaishnava, Prashant
A2  - Leon, Martin B.
A2  - Callans, David J.
A2  - Rumsfeld, John S.
A2  - Poppas, Athena
PY  - 2022
T2  - Fuster and Hurst's The Heart, 15e
AB  - Content  UpdateSELECT  Trial:  Semaglutide  in  the  High-Risk  Non-Diabetic  Obese  PopulationGlucagon-like  peptide-1  (GLP-1)  agonists,  such  as  semaglutide,  reduce  the  risk  of  major  adverse  cardiovascular  events  in  patients  with  diabetes.  Read  More  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesscardiology.mhmedical.com/content.aspx?aid=1205976467
ER  -